A pipeline that protects futures
We are building a strong pipeline of targeted therapies designed
specifically for children with cancer. And we’re working hard to develop these medicines with rigor and efficiency to get them to those who need them most.
A pipeline that protects futures
We are building a strong pipeline of targeted therapies designed
specifically for children with cancer. And we’re working hard to develop these medicines with rigor and efficiency to get them to those who need them most.
Our treatments have the potential to save lives, our pipeline aims to protect futures and our commitment aspires to elevate what can be achieved in oncology.
- Pre-Clinical Pre-CN
- Ph 1 Phase 1
- Ph 2 Phase 2
- Ph 3 Phase 3
Indication: Relapsed pLGG
Progress: Phase 2
Clinical Trial: Enrolling (FIREFLY-1) 1
- PH2
Indication: Frontline pLGG
Progress: Phase 3
Clinical Trial: Enrolling (FIREFLY-2)
- PH3
Indication: MAPK-altered solid tumors 3*
Progress: Phase 1
Clinical Trial: Enrolling (FIRELIGHT-1)4
- PH1
Indication: Pediatric and adult cancers 5*
Progress: Pre-Clinical
Clinical Trial:
- PreCN
1 FIREFLY-1 is a pivotal Phase 2 trial expected to support registration.
2 DAY101 adult monotherapy Phase 1 dose escalation and expansion trial previously completed.
3 Pimasertib Phase 1 dose escalation and expansion trial previously completed.
4 Trial in combination with DAY101.
5 Research collaboration and license agreement with Sprint Bioscience for exclusive worldwide rights to a research-stage program targeting VRK1.
* Includes patients ≥12 years of age.